Industry Overview - In 2024, the A-share pharmaceutical industry is projected to achieve a total revenue of 2.42 trillion yuan, marking a 1.0% year-on-year decline, the first decrease in recent years [1] - The net profit attributable to shareholders is expected to be 140.4 billion yuan, representing a significant year-on-year drop of nearly 12%, the first negative growth in five years [1] - The domestic pharmaceutical market has entered a phase of stock competition, with stricter medical insurance cost control and centralized procurement becoming the norm [1][2] Company Strategy - As a leading digital comprehensive service platform in the outpatient pharmaceutical industry, the company has launched the "Upward Move" strategy in 2023, focusing on enriching products, deepening brand cooperation, and building proprietary brands [1][3] - The company achieved a revenue of 17.904 billion yuan in 2024, a year-on-year increase of 5.5%, and its net profit turned positive for the first time, reaching 30.01 million yuan [3][4] - The company has covered 491,000 pharmacies and 330,000 grassroots medical institutions, penetrating 98.9% of county-level areas and 91.2% of townships, showcasing its extensive channel advantages [4] Market Dynamics - The number of retail pharmacies in China has reached a turning point, with a total of 700,881 pharmacies as of Q4 2024, reflecting a year-on-year growth of 2.3% but a quarter-on-quarter decline of 0.5% [2] - The closure rate of pharmacies in 2024 is approximately 5.76%, up from 3.8% in 2023, indicating an accelerating trend of store closures [2] - The retail terminal drug sales scale is expected to reach 574 billion yuan in 2024, with a year-on-year growth of 3.7%, while drug sales growth is at 2.3% [2] Product Development - The company has expanded its exclusive strategic cooperation brands and proprietary brand products to over 830 SKUs in 2024, with a transaction scale of 651 million yuan, a year-on-year increase of approximately 152% [6] - The proprietary brand "Le Yaoshi" has over 250 varieties and has achieved significant market penetration, with annual sales exceeding 38 million yuan for a key product [6][7] - The self-operated business has seen a compound annual growth rate of 78% from 2021 to 2023, with the annual GMV increasing from 83 million yuan to 263 million yuan [7] Consumer Behavior - In the stock economy era, the price-performance ratio has become the primary factor influencing consumer behavior, reflecting a shift towards more rational and cautious purchasing decisions [8] - The pharmaceutical consumption market, perceived as a necessity, is also showing signs of fatigue as consumer income expectations change [8]
药师帮“向上走”：深耕供应链，驱动韧性增长